Last reviewed · How we verify
hCT-MSC
At a glance
| Generic name | hCT-MSC |
|---|---|
| Sponsor | Joanne Kurtzberg, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
- Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder (PHASE1)
- MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs (PHASE2)
- hCT-MSC Infusion in Adults With Autism Spectrum Disorder (PHASE1)
- Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function (PHASE2)
- Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE (PHASE1)
- hCT-MSC in Children With Autism Spectrum Disorder (PHASE2)
- hCT-MSCs for COVID19 ARDS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hCT-MSC CI brief — competitive landscape report
- hCT-MSC updates RSS · CI watch RSS
- Joanne Kurtzberg, MD portfolio CI